Fig. 1From: Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinomaFlow of participants in the AGITG DOCTOR TrialBack to article page